HIV Infections
Conditions
Keywords
Drug Therapy, Combination, Nevirapine, HIV Protease Inhibitors, Ritonavir, Reverse Transcriptase Inhibitors
Brief summary
The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected patients who previously have taken protease inhibitors. This study also examines how the body handles this combination of anti-HIV drugs.
Interventions
DRUGLopinavir/Ritonavir
DRUGNevirapine
Sponsors
Abbott
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Concurrent Medication: Allowed: \- Antiretroviral regimen containing a protease inhibitor and one or two nucleoside reverse transcriptase inhibitors that has not changed in the last 12 weeks. Patients must have: \- HIV infection with plasma HIV RNA of at least 1,000 copies/ml and less than or equal to 100,000 copies/ml at screening. Prior Medication: Allowed: Naive to or has had less than 8 weeks of at least one nucleoside reverse transcriptase inhibitor and an acceptable regimen of two nucleoside reverse transcriptase inhibitors.
Exclusion criteria
Concurrent Medication: Excluded: * Medications that are contraindicated with ABT-378/ritonavir for the duration of the study, such as midazolam, triazolam, terfenadine, astemizole, cisapride, pimozide, ergotamine and dihydroergotamine. * Over-the-counter medicine or alcohol, without knowledge or permission of the investigator. Patients with the following prior conditions are excluded: * Evidence of acute illness determined by vital signs, physical examination, or laboratory results. * Clinically significant abnormal ECG results. * Positive test result for drug abuse with the exception of cannabis, unless the investigator anticipates cannabis use will interfere with compliance with the study. Prior Medication: Excluded: * Investigational drugs with the exception of Amprenavir within 28 days prior to the initiation of study dosing. * Treatment with a non-nucleoside reverse transcriptase inhibitor. * Treatment with a protease inhibitor different from the current protease inhibitor for more than 6 weeks prior to current regimen. * Treatment with more than one protease inhibitor concurrently. Risk Behavior: Excluded: * Active substance abuse, alcohol abuse, psychiatric illness. * Presumption, by investigator, of poor compliance to regimen.
Countries
United States
Outcome results
None listed